Medpace Holdings, Inc. Direct Operating Costs
Medpace Holdings, Inc. (MEDP) reported Direct Operating Costs of $505.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCosts · last filed 2026-07-23
- Medpace Holdings, Inc. direct operating costs for the quarter ending 2026-06-30 was $505.69M, a 19.47% increase year-over-year.
- Medpace Holdings, Inc. direct operating costs for the quarter ending 2026-03-31 was $510.28M, a 34.21% increase year-over-year.
- Medpace Holdings, Inc. direct operating costs for the quarter ending 2025-12-31 was $503.13M, a 40.43% increase year-over-year.
- Medpace Holdings, Inc. direct operating costs for the quarter ending 2025-09-30 was $462.96M, a 27.08% increase year-over-year.
- Medpace Holdings, Inc. direct operating costs for fiscal 2025 was $1.77B, a 21.81% increase from fiscal 2024.
- Medpace Holdings, Inc. direct operating costs for fiscal 2024 was $1.45B, a 6.71% increase from fiscal 2023.
- Medpace Holdings, Inc. direct operating costs for fiscal 2023 was $1.36B, a 32.48% increase from fiscal 2022.
- Medpace Holdings, Inc. direct operating costs for fiscal 2022 was $1.03B, a 26.20% increase from fiscal 2021.
| Period end | Direct Operating Costs 3 month | Direct Operating Costs 6 month | Direct Operating Costs 9 month | Direct Operating Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $505.69M 10-Q · filed 2026-07-23 | $1.02B 10-Q · filed 2026-07-23 | $1.52B derived: sum of 3 quarters · filed 2026-07-23 | $1.98B derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $510.28M 10-Q · filed 2026-04-23 | $1.01B derived: sum of 2 quarters · filed 2026-04-23 | $1.48B derived: sum of 3 quarters · filed 2026-04-23 | $1.90B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $503.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $966.10M derived: sum of 2 quarters · filed 2026-02-10 | $1.39B derived: sum of 3 quarters · filed 2026-07-23 | $1.77B 10-K · filed 2026-02-10 |
| 2025-09-30 | $462.96M 10-Q · filed 2025-10-23 | $886.26M derived: sum of 2 quarters · filed 2026-07-23 | $1.27B 10-Q · filed 2025-10-23 | $1.62B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $423.30M 10-Q · filed 2026-07-23 | $803.52M 10-Q · filed 2026-07-23 | $1.16B derived: sum of 3 quarters · filed 2026-07-23 | $1.53B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $380.22M 10-Q · filed 2026-04-23 | $738.49M derived: sum of 2 quarters · filed 2026-04-23 | $1.10B derived: sum of 3 quarters · filed 2026-04-23 | $1.48B derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $358.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $722.58M derived: sum of 2 quarters · filed 2026-02-10 | $1.10B derived: sum of 3 quarters · filed 2026-02-10 | $1.45B 10-K · filed 2026-02-10 |
| 2024-09-30 | $364.31M 10-Q · filed 2025-10-23 | $738.58M derived: sum of 2 quarters · filed 2025-10-23 | $1.09B 10-Q · filed 2025-10-23 | $1.46B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $374.27M 10-Q · filed 2025-07-22 | $730.17M 10-Q · filed 2025-07-22 | $1.09B derived: sum of 3 quarters · filed 2026-02-10 | $1.45B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $355.90M 10-Q · filed 2025-04-22 | $717.50M derived: sum of 2 quarters · filed 2026-02-10 | $1.08B derived: sum of 3 quarters · filed 2026-02-10 | $1.41B derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $361.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $720.90M derived: sum of 2 quarters · filed 2026-02-10 | $1.06B derived: sum of 3 quarters · filed 2026-02-10 | $1.36B 10-K · filed 2026-02-10 |
| 2023-09-30 | $359.31M 10-Q · filed 2024-10-22 | $695.86M derived: sum of 2 quarters · filed 2024-10-22 | $999.74M 10-Q · filed 2024-10-22 | $1.28B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $336.55M 10-Q · filed 2024-07-23 | $640.44M 10-Q · filed 2024-07-23 | $918.80M derived: sum of 3 quarters · filed 2025-02-11 | $1.18B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $303.88M 10-Q · filed 2024-04-23 | $582.25M derived: sum of 2 quarters · filed 2025-02-11 | $846.96M derived: sum of 3 quarters · filed 2025-02-11 | $1.10B derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $278.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $543.08M derived: sum of 2 quarters · filed 2025-02-11 | $795.29M derived: sum of 3 quarters · filed 2025-02-11 | $1.03B 10-K · filed 2025-02-11 |
| 2022-09-30 | $264.71M 10-Q · filed 2023-10-24 | $516.92M derived: sum of 2 quarters · filed 2023-10-24 | $749.19M 10-Q · filed 2023-10-24 | $969.76M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $252.21M 10-Q · filed 2023-07-25 | $484.48M 10-Q · filed 2023-07-25 | $705.05M derived: sum of 3 quarters · filed 2024-02-13 | $913.52M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $232.27M 10-Q · filed 2023-04-25 | $452.84M derived: sum of 2 quarters · filed 2024-02-13 | $661.31M derived: sum of 3 quarters · filed 2024-02-13 | $864.95M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $220.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $429.04M derived: sum of 2 quarters · filed 2024-02-13 | $632.68M derived: sum of 3 quarters · filed 2024-02-13 | $814.22M 10-K · filed 2024-02-13 |
| 2021-09-30 | $208.47M 10-Q · filed 2022-10-25 | $412.12M derived: sum of 2 quarters · filed 2022-10-25 | $593.65M 10-Q · filed 2022-10-25 | $770.48M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $203.64M 10-Q · filed 2022-07-26 | $385.18M 10-Q · filed 2022-07-26 | $562.01M derived: sum of 3 quarters · filed 2023-02-14 | $718.22M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $181.54M 10-Q · filed 2022-04-26 | $358.36M derived: sum of 2 quarters · filed 2023-02-14 | $514.58M derived: sum of 3 quarters · filed 2023-02-14 | $662.94M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $176.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $333.04M derived: sum of 2 quarters · filed 2023-02-14 | $481.40M derived: sum of 3 quarters · filed 2023-02-14 | $647.20M 10-K · filed 2023-02-14 |
| 2020-09-30 | $156.21M 10-Q · filed 2021-10-26 | $304.57M derived: sum of 2 quarters · filed 2021-10-26 | $470.37M 10-Q · filed 2021-10-26 | $637.56M derived: sum of 4 quarters · filed 2021-10-26 |
| 2020-06-30 | $148.36M 10-Q · filed 2021-07-27 | $314.16M 10-Q · filed 2021-07-27 | $481.35M derived: sum of 3 quarters · filed 2021-07-27 | $633.42M derived: sum of 4 quarters · filed 2021-07-27 |
| 2020-03-31 | $165.80M 10-Q · filed 2021-04-27 | $332.99M derived: sum of 2 quarters · filed 2021-04-27 | $485.06M derived: sum of 3 quarters · filed 2021-04-27 | $635.37M derived: sum of 4 quarters · filed 2021-04-27 |
| 2019-12-31 | $167.19M 10-K · filed 2020-02-25 | $319.26M derived: sum of 2 quarters · filed 2020-10-27 | $469.57M derived: sum of 3 quarters · filed 2020-10-27 | $615.27M 10-K · filed 2022-02-15 |
| 2019-09-30 | $152.07M 10-Q · filed 2020-10-27 | $302.38M derived: sum of 2 quarters · filed 2020-10-27 | $448.08M 10-Q · filed 2020-10-27 | $579.22M derived: sum of 4 quarters · filed 2020-10-27 |
| 2019-06-30 | $150.31M 10-Q · filed 2020-07-28 | $296.01M 10-Q · filed 2020-07-28 | $427.15M derived: sum of 3 quarters · filed 2020-07-28 | $551.14M derived: sum of 4 quarters · filed 2020-07-28 |
| 2019-03-31 | $145.70M 10-Q · filed 2020-04-29 | $276.84M derived: sum of 2 quarters · filed 2020-04-29 | $400.83M derived: sum of 3 quarters · filed 2020-04-29 | $517.51M derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | $131.13M 10-K · filed 2020-02-25 | $255.13M derived: sum of 2 quarters · filed 2020-02-25 | $371.81M derived: sum of 3 quarters · filed 2020-02-25 | $489.06M 10-K · filed 2021-02-16 |
| 2018-09-30 | $124.00M 10-K · filed 2020-02-25 | $240.67M derived: sum of 2 quarters · filed 2020-02-25 | $357.93M 10-Q · filed 2019-10-29 | $426.73M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $116.68M 10-K · filed 2020-02-25 | $233.93M 10-Q · filed 2019-07-30 | $302.73M derived: sum of 3 quarters · filed 2020-02-25 | $367.84M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $117.25M 10-K · filed 2020-02-25 | $186.06M derived: sum of 2 quarters · filed 2020-02-25 | $251.16M derived: sum of 3 quarters · filed 2020-02-25 | $314.78M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $68.80M 10-K · filed 2019-02-26 | $133.91M derived: sum of 2 quarters · filed 2019-02-26 | $197.53M derived: sum of 3 quarters · filed 2019-02-26 | $261.46M 10-K · filed 2020-02-25 |
| 2017-09-30 | $65.11M 10-K · filed 2019-02-26 | $128.72M derived: sum of 2 quarters · filed 2019-02-26 | $192.66M 10-Q · filed 2018-10-30 | |
| 2017-06-30 | $63.62M 10-K · filed 2019-02-26 | $127.55M 10-Q · filed 2018-07-31 | ||
| 2017-03-31 | $63.94M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $249.47M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |